p16 (CDKN2/MTS1) gene deletions are rare in prostatic carcinomas in the United States and Japan

Journal of Urology

Volumn 157, Issue 3, 1997, Pages 1117-1120

  Mangold, Kathy A ^b   Takahashi, Hiroyuki ^b   Brandigi, Claus ^b   Wada, Tetsuro ^b   Wakui, Shin ^b   Furusato, Masakuni ^b   Boyd, Jeff ^b   Chandler, Francis W ^b   Allsbrook Jr , William C ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b NONE

Author keywords

p16 CDKN2 MTS1; prostatic neoplasms; tumor suppressor genes

Indexed keywords

ARTICLE; CARCINOGENESIS; DNA TEMPLATE; EXON; GENE AMPLIFICATION; GENE DELETION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; JAPAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR SUPPRESSOR GENE; UNITED STATES;

EID: 0031031325     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65152-8     Document Type: Article

References (25)

1. Parker, S. L., Tong, T., Bolden, S. and Wingo, P. A.: Cancer statistics, 1996. CA: Cancer J. Clin., 46: 5, 1996.
2. Whittemore, A. S.: Prostate Cancer. Cancer Surveys, 19/20: 309, 1994.
3. Ries, L. A. G., Miller, B. A., Hankey, B. F., Kosary, C. L., Harras, A. and Edwards, B. K. (eds): SEER Cancers Statistics Review, 1973-1991: Tables and Graphs, National Cancer Institute. Washington, D.C.: U.S. Government Printing Office, NIH Pub. No. 94-2789, p. 369, 1994.
4. Konishi, N., Enomoto, T., Buzard, G., Ohshima, M., Ward, J. M. and Rice, J. M.: K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men. Cancer, 69: 2293, 1992.
5. Peehl, D. M., Wehner, N. and Stamey, T. A.: Activated Ki-ras oncogene in human prostatic adenocarcinoma. Prostate, 10: 281, 1987.
6. Carter, B. S., Epstein, J. I. and Isaacs, W. B.: ras gene mutations in human prostate cancer. Cancer Res., 50: 6830, 1990.
7. Takahashi, H., Furusato, M., Allsbrook, W. C., Jr., Nishii, H., Wakui, S., Barrett, J. C. and Boyd, J.: Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men. Cancer Res., 55: 1621, 1995.
8. Liu, Q., Neuhausen, S., McClure, M., Frye, C., Weaver-Feldhaus, J., Gruis, N. A., Eddington, K., Allalunish-Turner, M. J., Skolnick, M. H., Fujimura, F. K. and Kamb, A.: CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene, 10: 1061, 1995.
9. Ink4 and retinoblastoma tumour-suppressor genes occur in distinct subsets of human cancer cell lines. Int. J. Cancer, 61: 115, 1995.
10. Igaki, H., Sasaki, H., Kishi, T., Sakamoto, H., Tachimori, Y, Kato, H., Watanabe, H., Sugimura, T. and Terada, M. Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines. Biochem. Biophys. Res. Comm., 203: 1090, 1994.
11. Liu, Q., Yan, Y. X., McClure, M., Nakagawa, H., Fujimura, F. and Rustgi, A. K.: MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. Oncogene, 10: 619, 1995.
12. Kamb, S., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E. and Skolnick, M. H.: A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264: 436, 1994.
13. Komiya A., Suzuki, H., Aida, S., Yatani, R. and Shimazaki, J.: Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines in human prostatic cancer. Jpn. J. Cancer Res., 86: 622, 1995.
14. Cheng, J. Q., Jhanwar, S. C., Klein, W. M., Bell, D. W., Lee, W. C., Altomare, D. A., Nobori, T., Olopade, O. I., Buckler, A. J. and Testa, J. R.: p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res., 54: 5547, 1994.
15. Hayashi, N., Sugimoto, Y., Tsuchiya, E., Ogawa, M. and Nakamura, Y.: Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4I (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem. Biophys. Res. Comm., 202: 1426, 1994.
16. Kai, M., Arakawa, H., Sugimoto, Y., Murata, Y., Ogawa, M. and Nakamura, Y.: Infrequent somatic mutation of the MTS1 gene in primary bladder carcinomas. Jpn. J. Cancer Res., 86: 249, 1995.
17. Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A., Ally, D. S., Sheahan, M. D., Clark, W. H., Jr., Tucker, M. A. and Dracopoli, N. C.: Germline p16 mutations in familial melanoma. Nature Genet., 8: 15, 1994.
18. Duro, D., Flexor, M. A., Bernard, O., d'Agay, M. F., Berger, R. and Larsen, C. J.: Alterations of the putative tumor suppressor gene p16/MTS1 in human hematological malignancies. Comptes Rendus Acad. Sci. - Ser. III Sci. Vie., 317: 913, 1994.
19. Sill, H., Goldman, J. M. and Cross, N. C.: Homozyqous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood, 85: 2013, 1995.
20. Cairns, P., Polascik, T. J., Eby, Y., Tokino, K., Califano, J., Merlo, A., Mao, L., Herath, J., Jenkins, R., Westra, W., Rutter, J. L., Buckler, A., Gabrielson, E., Tockman, M., Cho, K. R., Hedrick, L., Bova, G. S., Isaacs, W., Koch, W., Schwab, D. and Sidransky, D.: Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genet. 11: 210, 1995.
21. INK4 in human cancer. Proc. Natl. Acad. Sci. USA, 91: 11045, 1994.
22. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J.-P. J., Davidson, N. E., Sidransky, D. and Baylin, S. B.: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525, 1995.
23. Gonzalez-Zulueta, M., Bender, C. M., Yang, A. S., Nguyen, T., Beart, R. W., Van Tornout, J. M. and Jones, P. A.: Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res., 55: 4531, 1995.
24. Harlow, S. P. and Stewart, C. C.: Quantitation of c-myc gene amplification by a competitive PCR assay system. PCR Meth. Appl., 3: 163, 1993.
25. Bassam, B. J., Caetano-Anollés, G. and Gresshoff, P. M.: Fast and sensitive silver staining of DNA in polyacrylamide gels. Anal. Biochem., 196: 80, 1991.